Abstract
Objective : To compare clinical outcome and costs of CC + gonadotropins with GnRHa + gonadotropins during IVF/ICSI cycles.
Materials and methods : Clinical outcome and expenses of 382 CC + gonadotropin and 964 GnRHa + gonadotropin cycles were compared. Medication costs were calculated on the basis of the mean number of ampoules and the proportion of various gonadotropins. Costs per clinical pregnancy were calculated on the basis of expenses and clinical pregnancy rates.
Results : Women in the CC + gonadotropin group were younger, and had fewer follicles, oocytes, embryos, and embryos transferred. Clinical pregnancy rates were higher in the GnRHa group (35.9 % vs 26.2%, p<0.001). More ampoules of gonadotropins were used in the GnRHa group (24.0 ± 0.3 vs 20.0 ± 0.5, p<0.001). Medication costs per cycle were higher in the GnRHa group (US$357 vs 248). Expenses per pregnancy</IT> however were lower in the GnRHa group (US$ 4197 vs 5335 with IVF; US$ 5590 vs 7244 with ICSI). When different age subgroups with similar baseline characteristics and stimulation parameters were compared, pregnancy rates were significantly higher in the GnRHa groups. Medication cost per cycle was higher in the GnRHa subgroups, and the expense per pregnancy was lower with GnRHa protocol.
Conclusions : Cost per cycle is higher with GnRHa + gonadotropin. However, because of the better performance of the GnRHa + gonadotropin stimulation, the cumulative costs are reduced by the time a clinical pregnancy is achieved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Lopata A, Johnston IW, Hoult IJ, Speirs AI: Pregnancy following intrauterine implantation of an embryo obtained by in vitro fertilization of a preovulatory egg. Fertil Steril 1980;33:117–120
Edwards RG, Steptoe PC, Purdy JM: Establishing full-term human pregnancies using cleaving embryos grow in vitro. Br J Obstet Gynaecol 1980;87:737–756
Adashi EY: Clomiphene citrate: Mechanism(s) and site(s) of action-a hypothesis revisited. Fertil Steril 1984;42:331–343
Reynolds AM, Schieve LA, Jeng G, Peterson HB: Does insurance coverage decrease the risk for multiple births associated with assisted reproductive technology? Fertil Steril 2003;80:16–23
Jain T, Harlow BL, Hornstein MD: Insurance coverage and outcomes of in vitro fertilization. N Engl J Med 2002;347:661–666
Steer CV, Mills CL, Tan SL, Campbell S, Edwards RG: The cumulative embryo score: A predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer programme. Hum Reprod 1992;7:117–119
Trounson AO, Leeton JF, Wood C, Webb J, Wood J: Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science 1981;212:681–682
Quigley MM, Schmidt CL, Beauchamp PJ, Pace-Owens S, Berkowitz AS, Wolf DP: Enhanced follicular recruitment in an in vitro fertilization program: Clomiphene alone versus a clomiphene/human menopausal gonadotropin combination. Fertil Steril 1984;42:25–33
Kemeter P, Feichtinger W: Experience with a new fixed-stimulation protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization. Hum Reprod 1989;4(8 Suppl):53–58
Wildt L, Diedrich K, van der Ven H, al Hasani S, Hubner H, Klasen R: Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins. Hum Reprod 1986;1:15–19
Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau C, Cristol P, Viala JL: Ovarian stimulation by a combination of gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47:639–643
Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D: Suppression of endogenous luteinizing hormone surge by the gonadotrophinreleasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788–791
Engel JB, Ludwig M, Felderbaum R, Albano C, Devroey P, Diedrich K: Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: A suitable approach to “friendly” IVF? Hum Reprod 2002;17:2022–2026
Williams SC, Gibbons WE, Muasher SJ, Oehninger S: Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of gonadotropin-releasing hormone antagonist. Fertil Steril 2002;78:1068–1072
Mansour RT, Aboulghar MA, Serour GI, Al-Inany HG, Fahmy I, Amin Y: The use of clomiphene citrate/human menopausal gonadotrophins in conjunction with GnRH antagonist in an IVF/ICSI program is not a cost effective protocol. Acta Obstet Gynecol Scand 2003;82:48–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kovacs, P., Matyas, S., Bernard, A. et al. Comparison of Clinical Outcome and Costs with CC + Gonadotropins and GnRHa + Gonadotropins During IVF/ICSI Cycles. J Assist Reprod Genet 21, 197–202 (2004). https://doi.org/10.1023/B:JARG.0000040234.21133.35
Issue Date:
DOI: https://doi.org/10.1023/B:JARG.0000040234.21133.35